Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Boehringer Ingelheim
Moodys
Merck
Express Scripts

Last Updated: January 28, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Olmutinib

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Olmutinib?

Olmutinib is an investigational drug.

There have been 6 clinical trials for Olmutinib. The most recent clinical trial was a Phase 1 trial, which was initiated on July 17th 2017.

The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and [disabled in preview]. The leading clinical trial sponsors are Hanmi Pharmaceutical Company Limited, Konkuk University Medical Center, and Boehringer Ingelheim.

There are five US patents protecting this investigational drug and ninety international patents.

Recent Clinical Trials for Olmutinib
TitleSponsorPhase
Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNAHanmi Pharmaceutical Company LimitedPhase 2
Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNAKonkuk University Medical CenterPhase 2
Olmutinib (BI 1482694) ADME StudyBoehringer IngelheimPhase 1

See all Olmutinib clinical trials

Clinical Trial Summary for Olmutinib

Top disease conditions for Olmutinib
Top clinical trial sponsors for Olmutinib

See all Olmutinib clinical trials

US Patents for Olmutinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Olmutinib   Start Trial Method for preparing thienopyrimidine compound and intermediates used therein HANMI PHARM. CO., LTD. (Hwaseong-si, KR)   Start Trial
Olmutinib   Start Trial Process for preparing thienopyrimidine compound and intermediates used therein HANMI PHARM. CO., LTD. (Hwaseongi-si, KR)   Start Trial
Olmutinib   Start Trial Fused pyrimidine derivatives for inhibition of tyrosine kinase activity Hanmi Science Co., Ltd (Hwaseong-si, KR)   Start Trial
Olmutinib   Start Trial Fused pyrimidine derivatives for inhibition of tyrosine kinase activity Hanmi Science Co., Ltd. (Hwaseong-Si, KR)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Olmutinib

Drugname Country Document Number Estimated Expiration Related US Patent
Olmutinib China 107108649 2034-12-30   Start Trial
Olmutinib European Patent Office 3224257 2034-12-30   Start Trial
Olmutinib Japan 2018502081 2034-12-30   Start Trial
Olmutinib South Korea 101803499 2034-12-30   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Boehringer Ingelheim
Harvard Business School
Johnson and Johnson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.